We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Genetic Link Found Between Immune System and Lymphoma

By LabMedica International staff writers
Posted on 12 Dec 2017
Classical Hodgkin lymphoma (cHL) is a lymphoid malignancy of germinal center (GC) B-cell origin, which is characterized by Hodgkin and Reed–Sternberg (HRS) cells with a dominant background population of reactive inflammatory cells.

People who inherit genetic changes that alter the function of their immune system are at increased risk of developing Hodgkin lymphoma. Of the four major subtypes of cHL, nodular sclerosis Hodgkin lymphoma (NSHL) and mixed cellularity Hodgkin lymphoma (MCHL) account for 65% and 20% of cHL, respectively.

A large group of scientists collaborating with The Institute of Cancer Research (London, UK) analyzed genetic data from 5,314 cases of Hodgkin lymphoma and 16,749 controls, from four different European studies. They analyzed constitutional DNA from 1,717 cases, which were genotyped using the Illumina Oncoarray (Illumina Inc, San Diego, CA, USA). The fidelity of genome-wide association study (GWAS) imputation was assessed by the concordance between imputed and directly genotyped single nucleotide polymorphisms (SNP) in a subset of samples. Replication genotyping of UK samples was performed using Polymerase Chain Reaction Kompetitive Allele Specific (PCR KASP) chemistry.

The investigators identified six new single-letter changes in DNA that were linked to the development of Hodgkin lymphoma and five of these affect the way a type of white blood cell, called B cells, develop. The study also showed clear differences in genetic risk between two different subtypes of Hodgkin Lymphoma and NSHL and MCHL. For example, a single-letter change located in DNA near the gene LIM Domain Containing Preferred Translocation Partner In Lipoma (LPP) increased the risk of NSHL by 37%, but had little effect on the risk of developing MCHL.

Richard S. Houlston, FMedSci, FRS, a Professor of Molecular and Population Genetics and senior author of the study, said, “Hodgkin lymphoma is a cancer of immune cells called B cells, and our study links the risk of the disease to changes in the genes that control how B cells develop. Interestingly, we found that some of the genetic changes we have linked to Hodgkin lymphoma have previously been associated with the risk of autoimmune diseases such as multiple sclerosis and rheumatoid arthritis. The new information could point towards new ways of diagnosing, treating, or even helping to prevent Hodgkin lymphoma.” The study was published on December 1, 2017, in the journal Nature Communications.

Related Links:
The Institute of Cancer Research
Illumina Oncoarray



Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Silver Member
Total Hemoglobin Monitoring System
GREENCARE Hb
New
Anti-HHV-6 IgM Assay
anti-HHV-6 IgM ELISA (semiquant.)
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get complete access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: The findings were based on patients from the ADAURA clinical trial of the targeted therapy osimertinib for patients with NSCLC with EGFR-activated mutations (Photo courtesy of YSM Multimedia Team)

Post-Treatment Blood Test Could Inform Future Cancer Therapy Decisions

In the ongoing advancement of personalized medicine, a new study has provided evidence supporting the use of a tool that detects cancer-derived molecules in the blood of lung cancer patients years after... Read more

Microbiology

view channel
Image: Schematic representation illustrating the key findings of the study (Photo courtesy of UNIST)

Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours

Rapid and precise identification of pathogenic microbes in patient samples is essential for the effective treatment of acute infectious diseases, such as sepsis. The fluorescence in situ hybridization... Read more

Industry

view channel
Image: Tumor-associated macrophages visualized using the Multiomic LS Assay (Photo courtesy of ACD)

Leica Biosystems and Bio-Techne Expand Spatial Multiomic Collaboration

Bio-Techne Corporation (Minneapolis, MN, USA) has expanded the longstanding partnership between its spatial biology brand, Advanced Cell Diagnostics (ACD, Newark, CA, USA), and Leica Biosystems (Nussloch,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.